67 / 116
775
16. Khanh T Ho and John D Reveille, The clinical
relevance of autoantibodies in scleroderma, Arthritis
Res
Ther
2003,
5:80-93
(DOI
10.1186/ar628)
.
17. T Dick, R Mierau, P Bartz-Bazzanella, M Alavi, M Stoyanova-
Scholz, J Kindler, E Genth, Coexistence of antitopoisomerase
I and anticentromere antibodies in patients with systemic
sclerosis, Ann Rheum Dis 2002;61:121–127
18. Beauvillain C, et al. Antineutrophil Cytoplasmic
Autoantibodies: How Should the Biologist Manage Them?,
Clinic Rev Allerg Immunol (2008) 35:47–58 DOI 10.1007/
s12016-007-8071-9.
19. Flores-Suárez L. Utilidad de los anticuerpos anticitoplasma de
neutrófilo en reumatología, Reumatol Clin. 2012;8(6):351–
357.
20. J. Savige et al. What do antineutrophil cytoplasmic
antibodies (ANCA) tell us? Best Practice & Research Clinical
Rheumatology Vol. 19, No. 2, pp. 263–276, 2005.
21. Mukhtyar C, et al. Outcomes from studies of antineutrophil
cytoplasm antibody associated vasculitis: a systematic
review by the European League Against Rheumatism systemic
vasculitis task force, Ann Rheum Dis 2008;67:1004–1010.
doi:10.1136/ard.2007.071936.
22. Damoiseaux J, et al. Evaluation of a New Fluorescent-Enzyme
Immuno-Assay for Diagnosis and Follow-up of ANCA-
Associated Vasculitis, Journal of Clinical Immunology, Vol.
25, No. 3, May 2005 (C 2005) DOI: 10.1007/s10875-005-
3863-2.
23. Abumohor P. Interpretación del Laboratorio en Reumatología.
Reumatología 2005; 21(4):201-205.
24. Westwood O, Nelson P. Rheumatoid factors: what’s new?
Rheumatology (Oxford) 2006; 45-379.
25. Shmerling R. The rheumatoid factor: an analysis of clinical
utility. Am J Med. 1991; 91 (5): 528.
26. Fabien N, et al. Prevalence of autoantibodies to cyclic
citrullinated peptide in patients whith rheumatic diseases
other than rheumatoid arthritis: a French multicenter study.
Clin Rev Allergy Immunol 2008; 34 (1):40.
27. Matsui T, et al. Diagnostic utility of anti-cyclic citrullinated
pepetide antiboidies for very early rheumatoid arthritis. J
Rheumatol 2006; 33 (12): 2390.
28. Kakumanu P, et al. Patients with pulmonary tuberculosis
are frequently positive for anti-cyclic citrullinated peptide
antibodies, but their sera also react with unmodified arginie-
containing peptide. Arthritis Rheum. 2008;58(6):1576.
29. Bernstein l. Allergy diagnostic testing: an updated practice
parameter.volumeme 100, number 3, supplements 3
Annals of allergy, Asthma & Immunology 2008: 100, n° 3,
supplement 3: 1-148.
30. Marinovic M. Capítulo 3: Evaluación de las patologías
alérgicas, Guzmán M. Alergias Guía Clínica, 2° edición,
Santiago, Mediterráneo, 2012: 47-59.
31. Caughey G. Tryptase genetics and anaphylaxis. J Allergy Clin
Immunol 2006; 117 (6):1411.
32. Didier le carrer. Serum protein electrophoresis
immunofixation, ilustrated interpretations. Chapter 1: Zone
electrphoresis, pag: 11-29.
33. The International Myeloma Working Group. Criteria for
the classification of monoclonal gammopathies, multiple
myeloma and related disorders: a report of the International
Myeloma Working Group. British Journal of Haematology,
2003, 121, 749–757.
34. Dispenzieri A et al. SPOTLIGHT REVIEW International Myeloma
Working Group guidelines for serum-free light chain analysis
in multiple myeloma and related disorders. Leukemia (2009)
23, 215–224.
[Laboratorio de Inmunología en la práctica clínica - Dra. Carla Bastías O. y cols.]